Article Per Year (5 Year)
p-Index From 2021 - 2026
3.138
P-Index
This Author published in this journals
All Journal Pharmaciana: Jurnal Kefarmasian JPSCR : Journal of Pharmaceutical Science and Clinical Research Jurnal Riset Kefarmasian Indonesia Jurnal Ilmiah Medicamento Jurnal Pengabdian Masyarakat Asia Jurnal Pengabdian kepada Masyarakat Pharmaceutical And Biomedical Sciences Journal (PBSJ) Usadha Journal of Pharmacy Borneo Journal of Pharmacy
Nyoman Budiartha Siada
Universitas Mahasaraswati Denpasar
Agriculture, Biological Sciences & Forestry Arts Humanities Biochemistry, Genetics & Molecular Biology Chemistry Computer Science & IT Economics, Econometrics & Finance Environmental Science Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Materials Science & Nanotechnology Medicine & Pharmacology Nursing Public Health Social Sciences Other

Published : 19 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 19 Documents
Search

 1   2 
Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review Meriyani, Herleeyana; Sanjaya, Dwi Arymbhi; Juanita, Rr. Asih; Siada, Nyoman Budiartha; Chusna, Nurul; Ketupapa, Florentina Gabriela
Borneo Journal of Pharmacy Vol. 8 No. 1 (2025): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v8i1.7913

Abstract

Triple-negative breast cancer is an aggressive and poor prognosis subtype of breast cancer. Eribulin has shown promise in the treatment of metastatic triple-negative breast cancer (mTNBC). This review aimed to provide a specific description, evidence, and discussion of the efficacy and safety of eribulin both as monotherapy and in combination with another agent in patients with mTNBC. The search was conducted in five databases (PubMed, ScienceDirect, PLoS One, Wiley Online Library, and Cochrane Library) towards published articles during the 2013-2023 period. A total of 237 articles were identified. After removing 69 duplicates, 168 articles underwent the screening process and 10 articles met the research criteria. Eribulin monotherapy effectiveness profile includes: overall survival (10.8-17.6 months), progression-free survival (2.8-3.2 months), partial response (21.0%-58.7%), progressive disease (15.5% -47.0%), and stable disease (28.8%-32%). However, there were no cases of complete response. Combination of eribulin with other agents' effectiveness profiles includes: overall survival (8.3-14.5 months), PFS (2.6-8.1 months), partial response (31.8-76.0%), complete response (2.4-8%), progressive disease (8.0-28%), and stable disease (8.0-52.3%). Eribulin monotherapy's safety profile is similar to that of combination therapy. No grade 5 adverse event was reported during monotherapy or in combination with other agents. The grade 4 adverse events reported are neutropenia, leukopenia, thrombocytopenia, anemia, peripheral neuropathy, fatigue, diarrhea, vomiting, dyspnea, back pain, arthralgia, febrile neutropenia, dyspnea, constipation, general physical health deterioration, alopecia. The all-grade adverse events with a percentage above 50% are neutropenia, leukopenia, thrombocytopenia, asthenia, alopecia, elevated AST, elevated ALT, hand-foot syndrome, fatigue, anemia, peripheral neuropathy, oral mucositis, and nausea.
Cross-resistance to antibiotics of Escherichia coli in the inpatient installation of general regional hospital “X” Bali, Indonesia Mahaputra, I Putu Yudistira; Sanjaya, Dwi Arymbhi; Meriyani, Herleeyana; Juanita, Rr Asih; Siada, Nyoman Budiartha; Kamalia, Made Gek Adisti; Adrianta, Ketut Agus; Noviani, Lusy
Pharmaciana Vol. 15 No. 1 (2025): Pharmaciana
Publisher : Universitas Ahmad Dahlan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.12928/pharmaciana.v15i1.29209

Abstract

Escherichia coli (E. coli) is a critical-priority group of MDR bacteria and its spread can occur in hospital inpatient settings. Several studies showed that antibiotics consumption for inpatients can cause E. coli resistance to other antibiotics called cross-resistance. The aim of this study to determine the cross-resistance in E. coli to antibiotics in the inpatient installation of the regional general hospital "X" in Bali, Indonesia by analyzing the relationship between the antibiotic consumption and the percentage of antibiotic resistance of E. coli. This research is an ecological study with the independent variable is the antibiotics consumption defined as defined daily doses/100 bed-days and the dependent variable is the percentage of E. coli resistance during 2017-2020. The correlation between the level of antibiotic consumption and the percentage of E. coli resistance to antibiotics was analyzed using the Pearson correlation tests. The results showed that the consumption of tetracycline had a significant correlation with increased resistance of E. coli to meropenem and piperacillin-tazobactam (r=0.8-1.0; p<0.05). This showed that there is cross-resistance in E. coli. This incident is associated with selective pressure, horizontal and vertical gene transfer in E. coli. The consumption of tetracycline, apart from inducing the production of the tet gene which is the cause of resistance to tetracycline, can also induce the production of resistance genes to broad-spectrum beta-lactam antibiotics such as piperacillin-tazobactam and meropenem.
Efektivitas dan Efek Samping pada Terapi Multi-Drug-Resistant Tuberculosis (MDR-TB): Kajian Literatur Sanjaya, Dwi Arymbhi; Meriyani, Herleeyana; Juanita, Rr. Asih; Siada, Nyoman Budiartha; Noviani, Lusy
Jurnal Ilmiah Medicamento Vol 11 No 1 (2025): Jurnal Ilmiah Medicamento
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v11i1.9685

Abstract

Multi-drug-resistant tuberculosis (MDR-TB) leads to a reduced cure rate for tuberculosis treatment. The global number of MDR-TB cases remained relatively stable between 2015 and 2020 but increased in 2021. In 2020, the World Health Organization (WHO) estimated 437,000 MDR-TB cases worldwide, which rose to 450,000 cases in 2021. Various treatment regimens recommended by the WHO require a review of the literature on the efficacy and side effects of drug use in MDR-TB. This review aims to provide updated information that can be used as a reference for the early identification and management of side effects. The article was a narrative review that collected and analyzed information from various international articles on databases such as PubMed, PlosOne, and ScienceDirect from January 2014 to June 2024. A total of six relevant articles were synthesized from 609 articles. The effectiveness of MDR-TB therapy with WHO-recommended drugs has shown a high cure rate (cured>50%). The incidence of side effects in MDR-TB therapy is smaller compared to the effectiveness of treatment. However, a study conducted at Wuhan Jinyintan Hospital in China from July 2019 to December 2020 showed that all study subjects experienced side effects. This included nausea and vomiting from protionamide, gatifloxacin, and ethambutol; hyperuricemia from pyrazinamide, and hyperpigmentation from clofazimine. It is recommended that a therapy regimen be selected based on culture test results, patient conditions, and drug availability in each country.
Faktor-Faktor yang Mempengaruhi Lama Rawat Inap Pasien Dengue Hemorrhagic Fever di Salah Satu Rumah Sakit Umum Daerah di Bali Siada, Nyoman Budiartha; Juanita, Rr Asih
Jurnal Ilmiah Medicamento Vol 11 No 1 (2025): Jurnal Ilmiah Medicamento
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v11i1.9852

Abstract

The World Health Organization (WHO) reported one to five million dengue infections from 2020 to 2022. According to Indonesian Health Profile data in 2020, the province of Bali had the highest Dengue Hemorrhagic Fever (DHF) Incidence Rate (IR), 273.1 morbidity, and a Case Fatality Rate (CFR) of 0.2%. The longer the patient's stay, the greater the costs are incurred for hospital treatment. Therefore, this study aims to analyze the factors influencing the length of stay of DHF patients with complications and comorbidities. This study was an observational study. Medical record data of DHF patients with complications and comorbidities were collected using a retrospective technique from January 2020 to December 2020 during hospitalization at a regional public hospital in Bali. The independent variables in this study include age, the severity of DHF, complications and comorbidities, and the amount of fluid therapy patients use during hospitalization. The dependent variable in this study is the patient's length of stay. The relationship between the independent and dependent variables was analyzed using logistic regression with a significance level set at p<0.05. There were 115 hospitalized DHF patients with complications and comorbidities, consisting of 52% males and 48% females. Most patients were in the age range of 6-11 years (43%). Based on the analysis that has been carried out, there is a factor that is significantly related to the length of stay of DHF patients, namely the use of the amount of fluid therapy (p=0.02). The findings of this study support the evaluation of DHF therapy, particularly in selecting the type and volume of fluids.
Penggunaan Antibiotik dan Resistensi Escherichia coli and Klebsiella pneumoniae: Studi Ekologikal Lima Tahun di Sebuah Rumah Sakit Umum Daerah Sanjaya, Dwi Arymbhi; Meriyani, Herleeyana; Juanita, Rr. Asih; Siada, Nyoman Budiartha; Mahaputra, Yudistira; Kamalia, Made Gek Adisti
Jurnal Ilmiah Medicamento Vol 11 No 2 (2025): Jurnal Ilmiah Medicamento (In progress)
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v11i2.11156

Abstract

Antibiotic resistance is a growing global health threat, partly driven by high antibiotic consumption. The World Health Organization (WHO) has identified critical-priority bacteria, including Escherichia coli and Klebsiella pneumoniae, due to their increasing resistance to multiple antibiotics. This study aimed to evaluate the correlation between antibiotic consumption and resistance rates in Escherichia coli and Klebsiella pneumoniae. This ecological study was conducted at a Regional Hospital in Indonesia based on retrospective inpatient data from January 2019 to December 2023. The population in this study is all data on systemic antibiotic consumption based on the J01 category of the Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) classification system and antibiogram from inpatient databases. Pearson and Spearman’s rank correlation analyses were performed to examine the associations between systemic antibiotic consumption levels and the percentage of Escherichia coli and Klebsiella pneumoniae resistance to other antibiotics. The most frequently used antibiotics were cefixime (305.664 DDD/100 bed-days), levofloxacin (139.552 DDD/100 bed-days), and ceftriaxone (109.805 DDD/100 bed-days). A strong and statistically significant correlation was observed between doxycycline consumption and Escherichia coli resistance to meropenem (r=0.894; p=0.041). Moreover, consumption levels of cefazolin, ceftazidime, cefepime, and ciprofloxacin were correlated with Escherichia coli resistance to ceftriaxone (p<0.05), while cefoperazone use demonstrated a very strong and statistically significant correlation with Escherichia coli resistance to ampicillin-sulbactam (r=0.952; p=0.012). Conversely, no significant correlation was found between antibiotic consumption and resistance in Klebsiella pneumoniae, suggesting that alternative factors such as intrinsic resistance mechanisms, mobile genetic elements, and environmental reservoirs may influence resistance development.
Antibiotic consumption and resistance: a 3-years ecological study for four critical groups of bacteria in a general regional hospital Sanjaya, Dwi Arymbhi; Siada, Nyoman Budiartha; Juanita, Rr Asih; Mahaputra, I Putu Yudistira; Kamalia, Made Gek Adisti; Meriyani, Herleeyana
Pharmaciana Vol. 14 No. 1 (2024): Pharmaciana
Publisher : Universitas Ahmad Dahlan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.12928/pharmaciana.v14i1.27321

Abstract

Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae are the most critical groups of multi-drug resistant (MDR) bacteria that cause a threat in hospitals. This study identified the trend of antibiotic consumption, antibiotic resistance pattern, and the relationship between antibiotic consumption and antibiotic resistance in a critical group of bacteria in a general regional hospital. This ecological study was based on retrospective data from inpatient databases in a general regional hospital over three years (2017-2019). The trend for annual antibiotic consumption over 2017-2019 was defined as defined daily doses/100 bed-days. The relationship between total antibiotic consumption and the percentage of antibiotic resistance among four isolated critical bacteria was explored in time series analysis and linear regression. The most frequently used antibiotic was ampicillin (220.33 DDD/100 bed-days), ciprofloxacin (126.86 DDD/100 bed-days), and ampicillin-sulbactam (126.34 DDD/100 bed-days). There was a significant relationship between antibiotic consumption (ampicillin, ampicillin-sulbactam, ceftazidime, gentamicin, amikacin, and ciprofloxacin) in DDD/100 bed-days and antibiotic resistance in E. coli, K. pneumoniae, and P. aeruginosa (p<0.05) but not statically significant in A. baumannii (p=0.062). The annual usage fluctuated or remained stable, with no statistically significant trends change. The relationship between antibiotic consumption and antibiotic resistance was significant in three out of four critical groups of bacteria.
The Impact of EG and DEG Cases on Sales of Over-The-Counter Syrup Mendra, Ni Nyoman Yudianti; Antari, Ni Putu Udayana; Siada, Nyoman Budiartha; Marwati, I Gusti Ayu
Pharmaceutical and Biomedical Sciences Journal (PBSJ) Vol. 5 No. 2 (2023)
Publisher : Pharmaceutical and Biomedical Sciences Journal (PBSJ)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15408/pbsj.v5i2.32013

Abstract

The Indonesian Food and Drug Authority (BPOM) investigated and listed safe and unsafe syrup products in response to the contamination of Ethylene Glycol (EG) and Diethylene Glycol (DEG), causing Acute Kidney Injury in pediatric patients. Unsafe products were recalled and removed from distribution, leading to uncertainty and panic among the public and significantly impacting over-the-counter syrup sales in several pharmacies. This retrospective observational study assessed the impact of EG and DEG contamination on the sales of over-the-counter syrup in Pharmacy X in South Denpasar. Data from three months before (August to October 18th, 2022) and three months following the official instruction was published (October 19th, 2022 to December 2022) were analyzed using Wilcoxon test. The findings reveal a staggering decline in the sales of over-the-counter syrup by 35,03% (p-value of 0.03). Moreover, there was a notable increase of prescriptions in powder forms. The contamination cases caused panic, resulting in changes in behavior and consumption patterns. Despite the availability of safety information on an official website, public hesitance toward syrup products persists, indicating the need to implement a more effective strategy to address misinformation and restore public trust. Each individual must be responsible for educating the public during crises to prevent the spread of misinformation, ultimately restoring trust and normal consumer behavior. Furthermore, efficient stock management should be implemented to anticipate potential health crises in the future proactively.
POLA PERESEPAN OBAT ANTIHIPERTENSI DI POLI RAWAT JALAN RUMAH SAKIT “X” DI BALI PERIODE TAHUN 2022 Mendra, Ni Nyoman Yudianti; Puspasari, I Gusti Ayu; Siada, Nyoman Budiartha
Usadha Journal of Pharmacy Vol. 3 No. 2 (2024): Mei
Publisher : Universitas Muhammadiyah Surakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.23917/ujp.v3i2.311

Abstract

Hipertensi merupakan salah satu penyakit kronis dengan tingkat kejadian yang tinggi dan beresiko menyebabkan komplikasi. Pengobatan dan peresepan obat yang rasional diperlukan untuk mengontrol tekanan darah pasien serta mencegah terjadinya komplikasi. Penelitian ini bertujuan untuk mengetahui pola peresepan dan rasionalitas terapi antihipertensi pada pasien rawat jalan di salah satu rumah sakit umum di Bali tahun 2022 dengan BPJS sebagai jaminan asuransi kesehatan. Penelitian ini merupakan penelitian deskriptif dengan pengambilan data secara retrospektif dimana teknik pengambilan sampelnya menggunakan purposive sampling. Kriteria inklusi dalam penelitian ini meliputi pasien hipertensi dengan dan tanpa komorbid, telah menjalani pengobatan minimal 3 bulan terapi pada periode Januari - Desember 2022. Rasionalitas terapi meliputi tepat obat, tepat pasien, tepat dosis, dan tepat interval waktu pemberian yang dinilai berdasarkan pedoman JNC 8 dan Konsensus Penatalaksanaan Hipertensi Tahun 2021. Berdasarkan data dari 368 pasien rawat jalan, antihipertensi yang diresepkan meliputi Angiotensin receptor blocker (ARB) dengan persentase 64,13%; Calsium Channel Blocker (CCB) 59,51%; Angiotensin Converting Enzim Inhibitor (ACEI) 16,85%; Beta Blocker 15,22% dan diuretik sebesar 0,81%. Pada hasil evaluasi peresepan obat antihipertensi diperoleh tepat obat sebanyak 98,64%, tepat pasien sebanyak 96,74%, tepat dosis sebanyak 100%, dan tepat interval waktu pemberian sebanyak 100%.
The Association between Resistance of Sepsis-Inducing Bacteria to First-Line Antibiotics and Sepsis Outcome: A Retrospective Cross-Sectional Study Meriyani, Herleeyana; Sanjaya, Dwi Arymbhi; Juanita, Rr. Asih; Siada, Nyoman Budiartha; Yudiartha, I Wayan Maysa; Suryawan, Kadek
Jurnal Ilmiah Medicamento Vol 12 No 1 (2026): Jurnal Ilmiah Medicamento (In progress)
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v12i1.13597

Abstract

Background: Sepsis is a significant infectious disease linked to high mortality rates. Several bacterial pathogens that cause sepsis have shown resistance to first-line antibiotics. This resistance in sepsis-causing bacteria to initial antibiotic agents threatens treatment success, elevating mortality risk, healthcare costs, and prolonged hospital stays.Objective: This study aimed to investigate the relationship between the resistance of sepsis-causing bacteria to first-line antibiotics and sepsis treatment outcomes.Methods: This cross-sectional study was a single-center retrospective study. Data were collected from sepsis patients admitted to the intensive care unit of a general hospital in Bali between 2022 and 2023. The patients included in this study were those with a positive bacterial infection, as provided in the culture result. Therapy outcomes were evaluated based on discharge status: improved or unimproved (deceased). The resistance of sepsis-causing bacteria to first-line antibiotics, including fluoroquinolones, third- and fourth-generation cephalosporins, piperacillin-tazobactam, and vancomycin, was assessed through blood cultures. The relationship between antibiotic resistance and therapy outcomes was analyzed using the Gamma correlation coefficient. This study included 57 of 108 sepsis patients, primarily male (57.89%) and older than 60 years (57.89%).Results: A strong, significant positive correlation was observed between the resistance of sepsis-causing bacteria to third-generation cephalosporins and therapy outcomes (p=0.001; r=0.637). In contrast, resistance to fluoroquinolones (p=0.108; r=0.387), fourth-generation cephalosporins (p=0.377; r=-0.199), piperacillin-tazobactam (p=0.816; r=-0.060), and vancomycin (p=0.911; r=0.030) did not significantly impact therapy outcomes. The outcome of sepsis therapy is associated with resistance of sepsis-causing bacteria to third-generation cephalosporins but not to fluoroquinolones, fourth-generation cephalosporins, piperacillin-tazobactam, or vancomycin. This study uses a relatively small sample size, which precludes subgroup analyses.Conclusion: Non-significant findings for some antibiotics may reflect insufficient power; further study is needed to assess the correlation between resistance of sepsis-causing bacteria to fluoroquinolones, fourth-generation cephalosporins, piperacillin-tazobactam, and vancomycin.
Co-Authors Agung Ari Chandra Wibawa Chusna, Nurul Debby Juliadi Dewa Ayu Ika Pramitha Dwi Arymbhi Sanjaya Gde Nyoman Astika Herleeyana Meriyani I Gede Made Suradnyana I Gusti Ayu Puspasari I Komang Gede Mahardika I Putu Yudistira Mahaputra Kamalia, Made Gek Adisti Ketupapa, Florentina Gabriela Ketut Agus Adrianta Made Gek Adisti Kamalia Mahaputra, I Putu Yudistira Mahaputra, Yudistira Marwati, I Gusti Ayu Mendra, Ni Nyoman Yudianti Meriyani, Herleeyana Ni Made Dharma Shantini Suena Ni Made Sukma Sanjiwani Ni Nyoman Yudianti Mendra Ni Putu Udayana Antari Noviani, Lusy Puspasari, I Gusti Ayu Putu Sukma Purnamasari RR. Asih Juanita Suradnyana, I Gede Made Suryawan, Kadek Triska Ananda Rahayu Yudiartha, I Wayan Maysa